Current investors

Created in 2015, TargEDys has benefited from investments from major players in the microbiome sphere: NCI, Pontifax, Seventure and Biocodex. These investments have allowed TargEDys to develop the science into finished products, and to make these products available to a large number of consumers through distribution agreements in several countries.
End of May 2023, the French family company Biocodex has acquired 100% of TargEDys shares, to consolidate the groups strong ambition in the Microbiome and accelerate TargEDys development globally.

 Clic here for more information. 


Biocodex is a French pharmaceutical company founded in 1953 to develop and market the world’s first probiotic yeast strain, Saccharomyces boulardii CNCM I-745®. Today, Biocodex focuses its business on three main areas: Microbiota care; Women’s health; Orphan diseases. With more than 1,600 employees, Biocodex generated net revenues of above €500 million in 2022, including 35% in France and 65% internationally. The group is present in 115 countries through wholly owned subsidiaries in 16 countries and a network of distributors worldwide.

Since 2019, Biocodex became a shareholder and board member of TargEDys. Soon after, Biocodex became the distributor of TargEDys’ leading PreciBiomic, Symbiosys Satylia®, in France, then in Portugal and Poland.

This website uses different types of cookies to enable, improve and monitor the use of our website. For more information see our cookie policy
By clicking accept or continuing to browse on our website, you consent to the use on your device of analytics, advertising and other tags/files.
Read about